600216 浙江医药
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,249,16412.01%7,794,1468,115,8059,129,0947,326,935
减:营业总成本2,131,38512.03%7,681,6667,482,0257,932,3016,516,358
    其中:营业成本1,508,81413.43%5,269,8795,318,2745,399,7364,283,391
               财务费用2,007-82.47%(17,488)(37,966)93,11070,066
               资产减值损失(26,260)92.87%(137,208)(117,141)(165,169)(129,541)
公允价值变动收益(6,963)-161.57%(10,099)(23,881)51,72630,477
投资收益(1,501)-148.12%(3,505)(32,626)41,815119,744
    其中:对联营企业和合营企业的投资收益(845)-50.16%(9,782)(3,806)(4,240)(648)
营业利润101,798-3.33%380,158504,6161,179,437882,635
利润总额101,044-1.29%363,279491,3881,153,532850,981
减:所得税费用21,68118.54%86,485128,775268,972191,336
净利润79,363-5.60%276,794362,614884,559659,645
减:非控股权益(30,286)2.74%(152,845)(176,956)(160,763)(57,755)
股东净利润109,650-3.44%429,640539,5701,045,322717,400

市场价值指针
每股收益 (元) *0.110-8.33%0.4500.5601.0900.750
每股派息 (元) *----0.1500.1700.3300.230
每股净资产 (元) *10.0923.60%9.9809.5949.0967.952
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容